News Conference News AHA 2025 Stress CMR Facilitates Diagnosis, Targeted Care in ANOCA: CorCMR Caitlin E. Cox November 14, 2025
News Conference News AHA 2025 Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD Todd Neale November 13, 2025
News Conference News AHA 2025 CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI Michael O'Riordan November 11, 2025
News Conference News AHA 2025 Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI Todd Neale November 09, 2025
News Conference News AHA 2025 Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN Michael O'Riordan November 08, 2025
News Conference News AHA 2025 One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients Todd Neale November 08, 2025
News Opinion Editor's Corner AHA 2025 What’s Going to Be Hot at AHA 2025? Michael O'Riordan November 05, 2025
News Conference News TCT 2025 DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES Yael L. Maxwell November 04, 2025
News Conference News TCT 2025 Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2 Todd Neale November 03, 2025
Presentation TCT 2025 TCT 1014: Cost-effectiveness of clopidogrel versus aspirin for chronic maintenance therapy after percutaneous coronary intervention: results from the HOST-EXAM Extended study Presenter: Jeehoon Kang October 28, 2025
Presentation TCT 2025 TCT 1008: Aspirin vs. Clopidogrel as Monotherapy for Secondary Prevention in Stable Coronary Artery Disease: An Updated Meta Analysis Presenter: Timothy Charles Shuey October 27, 2025
Presentation TCT 2025 TCT 997: Long-Term Clopidogrel vs Aspirin Monotherapy in coronary artery disease patients with High Ischemic Risk: HOST-EXAM Extended Study Post Hoc Analysis Presenter: Jin-Eun Song October 27, 2025
News Conference News TCT 2025 More Data on Tricuspid Valve Interventions Reassure, yet Questions Remain Yael L. Maxwell October 26, 2025
Presentation TCT 2025 TCT 55: A Meta-Analysis on Safety and Efficacy of P2Y12 Inhibitor Monotherapy versus Aspirin Monotherapy After 12 Months of DAPT in Patients Post Percutaneous Coronary Intervention Presenter: Asna Aafreen October 26, 2025
Presentation TCT 2025 TCT 226: Aspirin Versus Clopidogrel Following Transcatheter Aortic Valve Replacement: A TVT Registry Propensity Matched Analysis Presenter: Yuri Pride October 25, 2025
Presentation TCT 2025 Clopidogrel Monotherapy Following 1-Month DAPT vs. Aspirin Monotherapy Following 12-Month DAPT After PCI in ACS Patients: Final 5-Year Results of the STOPDAPT-2 ACS Trial Presenter: Hirotoshi Watanabe October 25, 2025
Presentation TCT 2025 Aspirin Monotherapy After 1-Month DAPT in High Bleeding Risk Patients Undergoing PCI: The TARGET SAFE Randomized Trial Presenter: Miaohan Qiu October 25, 2025
News Daily News Getting Ready for a Heart Failure Polypill, Well Before the Data Are In Todd Neale October 16, 2025
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for September 2025 Michael O'Riordan September 30, 2025
News Conference News ESC 2025 ALONE-AF: Less Bleeding When OAC Stopped After Successful Ablation Todd Neale September 08, 2025